Review
Public, Environmental & Occupational Health
Li Cai, Xinyi Hu, Shuang Liu, Lei Wang, Hao Lu, Hua Tu, Xibao Huang, Yeqing Tong
Summary: Chikungunya fever is an acute infectious disease caused by Chikungunya virus (CHIKV) that is transmitted by Aedes aegypti mosquitoes. It has spread from Africa to South Asia, the Indian Ocean islands, and the Americas, now present in over 100 countries and territories worldwide, with approximately 1 million infections each year. The lack of preventive vaccines and approved antiviral treatments make CHIKV a major global health threat.
FRONTIERS IN PUBLIC HEALTH
(2023)
Review
Virology
Yalda Lucero, David O. Matson, Shai Ashkenazi, Sergio George, Miguel O'Ryan
Summary: Research on Human Norovirus continues to deepen our understanding of its biological and disease spectrum, but limitations in effectively replicating and propagating the virus hinder progress in several areas. Current areas of interest include clinical and molecular epidemiology, viral-host interactions, antiviral drugs, and vaccine development. The impact of the COVID-19 pandemic on Norovirus infection and disease is also a subject of reflection.
Review
Immunology
Jue Hou, Weijian Ye, Jianzhu Chen
Summary: Dengue is a common mosquito-borne disease caused by four closely related viruses. Developing a vaccine that can protect against all four virus strains without adverse effects is a challenge. Several tetravalent live attenuated vaccine candidates have entered clinical trials.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Sivaneswari Selvarajoo, Jonathan Wee Kent Liew, Tock H. Chua, Wing Tan, Rafdzah Ahmad Zaki, Romano Ngui, Wan Yusoff Wan Sulaiman, Poo Soon Ong, Indra Vythilingam
Summary: This study found that using a combination of gravid oviposition sticky (GOS) traps and dengue non-structural 1 (NS1) antigen testing can effectively reduce the occurrence of dengue cases by early surveillance of Aedes mosquitoes. The study also showed that this surveillance method significantly improved participants' knowledge, attitude, and practice towards dengue control.
SCIENTIFIC REPORTS
(2022)
Article
Immunology
Scott B. Halstead
Summary: In tropical and subtropical countries, four dengue viruses can cause severe disease, but the development of vaccines has been slow. Three tetravalent dengue vaccines have reached phase 3 clinical trials, but their effectiveness varies against different dengue virus types. A novel vaccine developed by the US National Institutes of Health has shown protective effects against dengue viruses in seronegative individuals during late-stage trials.
CLINICAL INFECTIOUS DISEASES
(2022)
Review
Medicine, Research & Experimental
Wen-Hung Wang, Aspiro Nayim Urbina, Chih-Yen Lin, Zih-Syuan Yang, Wanchai Assavalapsakul, Arunee Thitithanyanont, Po-Liang Lu, Yen-Hsu Chen, Sheng-Fan Wang
Summary: The development of dengue vaccines is crucial in preventing and controlling the global health threat caused by Dengue virus. Current approved vaccines have demonstrated low efficacy in certain populations, leading to ongoing investigation and development of novel strategies for dengue vaccines.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Immunology
Jarin Taslem Mourosi, Ayobami Awe, Swati Jain, Himanshu Batra
Summary: Dengue virus and Zika virus are mosquito-borne viruses that can cause severe diseases. There are no approved vaccines for these viruses, but there are several potential candidates in clinical trials, including nucleic acid vaccines.
Article
Multidisciplinary Sciences
Natchaya Kunanitthaworn, Oramai Mueangmo, Jutamad Saheng, Worawan Wongjak, Tanin Lertsiriladakul, Tanachot Chaito, Pasawat Nantarat, Tavitiya Sudjaritruk
Summary: This cross-sectional study aimed to assess the prevalence of hepatitis A virus (HAV) antibodies among children and adolescents in Chiang Mai, Thailand, and identify factors associated with HAV seropositivity. The study found that previous HAV vaccination and overweight were significantly associated with HAV seropositivity.
SCIENTIFIC REPORTS
(2023)
Article
Virology
Naoko Uno, Ted M. Ross
Summary: The study developed four independent DENV envelope glycoproteins using COBRA methodology to induce broadly neutralizing antibodies against all four serotypes, demonstrating a broad protective immune response in rhesus macaques.
JOURNAL OF VIROLOGY
(2021)
Article
Immunology
Ramil R. Mintaev, Dina V. Glazkova, Olga V. Orlova, Georgiy M. Ignatyev, Alexey S. Oksanich, German A. Shipulin, Elena V. Bogoslovskaya
Summary: Dengue fever is a global health problem, affecting over 100 million people annually. Vaccination is the most effective prevention strategy, but the development of vaccines is hindered by the risk of antibody-dependent enhancement. This article presents the development of an MVA-d34 vaccine against dengue virus, using safe and effective MVA viral vector. The vaccine targets the DIII domains of the envelope protein, which do not cause enhanced infection. Immunized mice generate a humoral response against all four dengue virus serotypes, and their sera have virus-neutralizing activity against dengue serotype 2. The MVA-d34 vaccine shows promise as a candidate vaccine against dengue fever.
Article
Infectious Diseases
Takahiro Nemoto, Maite Aubry, Yoann Teissier, Richard Paul, Van-Mai Cao-Lormeau, Henrik Salje, Simon Cauchemez
Summary: This study analyzed 35 years of dengue data in French Polynesia, revealing the impact of serotype, age, and changes in surveillance systems on disease risk. The study found heterogeneity in reporting probabilities by serotype, as well as a correlation between reporting probabilities and age and number of infections.
PLOS NEGLECTED TROPICAL DISEASES
(2022)
Review
Infectious Diseases
Chung-Hao Huang, Yu-Te Tsai, Seng-Fan Wang, Wen-Hung Wang, Yen-Hsu Chen
Summary: Development of efficient dengue vaccines is still lacking despite the presence of licensed vaccines like CYD-TDV. Efforts are being made to improve vaccine efficacy and eliminate the risk of severe dengue through heterologous prime-boost regimens. Additionally, the absence of an ideal animal model remains a challenge in dengue vaccine development.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
(2021)
Article
Immunology
Amina Basheer, Syed Babar Jamal, Badr Alzahrani, Muhammad Faheem
Summary: Dengue fever is a mosquito-borne disease that affects approximately 3.9 billion people globally each year. Currently, there is no available vaccine or drug for dengue virus infection. In this study, researchers designed a tetravalent subunit multi-epitope vaccine targeting different proteins from each serotype. The vaccine has shown potential to elicit a strong immune response against all dengue serotypes without causing any adverse effects.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Fengfu Cui, Feiwu He, Xiaorong Huang, Lina Tian, Saiqiang Li, Chumin Liang, Lilian Zeng, Huifang Lin, Juan Su, Liping Liu, Wei Zhao, Limei Sun, Lifeng Lin, Jiufeng Sun
Summary: Guangdong is a high-risk area for dengue, with seasonal transmission mainly triggered by imported cases. The highest risk period for local outbreaks is from August to September, affecting young and middle-aged adults. Dengue virus serotype 1 (DENV 1) has been the dominant serotype, with an increasing tendency of DENV 2. Local outbreaks of DENV 3 are rare, and DENV 4 is only found in imported cases. Early detection, case management, and precise control strategies are key for preventing local dengue transmission.
FRONTIERS IN MEDICINE
(2022)
Review
Pediatrics
Silvia Nunes Szente Fonseca
Summary: Dengue is a significant global public health issue, affecting 390 million people in 128 countries each year. Recent findings indicate a rise in dengue cases, severe dengue, and deaths in children, particularly in Brazil and Colombia. Co-infections of dengue and COVID-19 have also been reported in South America. While there is no specific treatment for dengue, there are licensed vaccines available for certain age groups, with ongoing research for further vaccine development.
CURRENT OPINION IN PEDIATRICS
(2023)